Almirall SA : € 200m non-pre-emptive capital increase to pursue bolt-on M&A deals
>Fresh capital to fund an M&A spree and keep the leverage at bay - Almirall’s board has resolved to carry out a capital increase for c. €200m by issuing new ordinary shares excluding the pre-emptive subscription rights, through an ABB directed to qualified investors. The ABB is expected to be finalised no later than 13 June at 8.00 a.m. CEST. The Gallardo family (59.7% stake) has undertaken to participate in the increase on a pro rata basis at the price derived from t...Almirall is engaged in the acquisition, manufacture, storage, sale and mediation in the sale of pharmaceutical specialties and products and all manner of raw materials used to prepare pharmaceutical specialties and products. Also, Co. acquires, manufactures, storages, sales and mediates in the sale of cosmetics, chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food-industry use, as well as all manner of utensils, complements and accessories for the chemical, pharmaceutical and clinical industries. In addition, Co. is engaged in the acquisition, sale, lease, subdivision and development of land lots, land and properties of all kinds.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.